Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mian Xi

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Nature Communications|March 1, 2024
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimabBaoqing Chen, Shiliang Liu, Yujia Zhu, et al.
The Lancet. Oncology|March 29, 2023
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trialYujia Zhu, Jing Wen, Qiaoqiao Li, et al.
Nature Communications|June 30, 2021
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trialShiliang Liu, Liling Luo, Lei Zhao, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2017
The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapyMian Xi, Cai Xu, Zhongxing Liao, et al.
Annals of Surgical Oncology|March 24, 2018
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal AdenocarcinomaLucas Goense, Peter S N van Rossum, Mian Xi, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 2023
A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 TrialTiantian Gao, Yong Yang, Zewei Zhang, et al.
Cancer Research and Treatment|May 5, 2026
Concurrent Chemoradiotherapy with or without Induction Chemoimmunotherapy in Unresectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World StudyBiqi Chen, Peiying Cen, Qi Cheng, et al.
Journal of Cancer|April 4, 2017
TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell CarcinomaShiLiang Liu, Bo Qiu, GuangYu Luo, et al.
Frontiers in Oncology|November 16, 2020
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-AnalysisYang-Xun Pan, Yi-Zhen Fu, Dan-Dan Hu, et al.
Eclinicalmedicine|August 10, 2023
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)Rui Chen, Qianwen Liu, Qiaoqiao Li, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Nature Communications|March 1, 2024
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimabBaoqing Chen, Shiliang Liu, Yujia Zhu, et al.
The Lancet. Oncology|March 29, 2023
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trialYujia Zhu, Jing Wen, Qiaoqiao Li, et al.
Nature Communications|June 30, 2021
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trialShiliang Liu, Liling Luo, Lei Zhao, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2017
The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapyMian Xi, Cai Xu, Zhongxing Liao, et al.
Annals of Surgical Oncology|March 24, 2018
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal AdenocarcinomaLucas Goense, Peter S N van Rossum, Mian Xi, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 2023
A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 TrialTiantian Gao, Yong Yang, Zewei Zhang, et al.
Cancer Research and Treatment|May 5, 2026
Concurrent Chemoradiotherapy with or without Induction Chemoimmunotherapy in Unresectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World StudyBiqi Chen, Peiying Cen, Qi Cheng, et al.
Journal of Cancer|April 4, 2017
TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell CarcinomaShiLiang Liu, Bo Qiu, GuangYu Luo, et al.
Frontiers in Oncology|November 16, 2020
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-AnalysisYang-Xun Pan, Yi-Zhen Fu, Dan-Dan Hu, et al.
Eclinicalmedicine|August 10, 2023
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)Rui Chen, Qianwen Liu, Qiaoqiao Li, et al.
Pageof 11